ZaBeCor Pharmaceutical Co.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ZaBeCor Pharmaceutical Co.
AstraZeneca moves syk kinase inhibitor into Phase III trials
AstraZeneca has enrolled the first patient in the pivotal programme for the first-in-class Syk kinase inhibitor fostamatinib (previously known as R778). Fostamatinib, which it licensed from Rigel Pharmaceuticals, is being evaluated as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).
Novartis enters RNAi area with Quark option deal
Novartis is to pay $10 million for the option to obtain the global licence to develop and commercialise Quark Pharmaceuticals' p53 temporary inhibitor small interfering RNA (siRNA) drug QPI-1002. The drug is currently in Phase II clinical trials for the prevention of acute kidney disease (AKI) in patients undergoing cardiac surgery and for delayed graft function (DGF) in kidney transplant patients.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice